[Rational basis for the use of alfa-2a recombinant interferon in the treatment of mycosis fungoides (MF)].
Mazza
P
P
Istituto di Ematologia, L. e A. Seràgnoli, Università, Bologna.
Bocchia
M
M
Zinzani
P L
PL
Gherlinzoni
F
F
Ghetti
P L
PL
D017977:Deltaretrovirus / Q000187:drug effects; D006800:Deltaretrovirus Infections / Q000150:complications / Q000628:therapy; D004341:Drug Evaluation; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D009182:Mycosis Fungoides / Q000209:etiology / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D014411:Neoplastic Stem Cells / Q000187:drug effects; D011994:Recombinant Proteins; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000473:pathology
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins